References
- Eleutério SJ, Senerchia AA, Almeida MT, et al. Osteosarcoma in
patients younger than 12 years old without metastases have similar
prognosis as adolescent and young adults. Pediatr Blood Cancer.
2015;62(7):1209-1213. doi:10.1002/pbc.25459
- Clark JC, Dass CR, Choong PF. A review of clinical and molecular
prognostic factors in osteosarcoma. J Cancer Res Clin Oncol.
2008;134(3):281-297. doi:10.1007/s00432-007-0330-x
- Bajpai J, Chandrasekharan A, Talreja V, et al. Outcomes in
non-metastatic treatment naive extremity osteosarcoma patients treated
with a novel non-high dosemethotrexate-based, dose-dense combination
chemotherapy regimen ’OGS-12’. Eur J Cancer. 2017;85:49-58.
doi:10.1016/j.ejca.2017.08.013
- Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of
alkaline phosphatase measurements in patients with osteogenic sarcoma
receiving chemotherapy. Cancer. 1979;43(6):2178-2181.
doi:10.1002/1097-0142(197906)43:6<2178::aid-cncr2820430603>3.0.co;2-9
- Li X, Ashana AO, Moretti VM, Lackman RD. The relation of tumour
necrosis and survival in patients with osteosarcoma. Int Orthop.
2011;35(12):1847-1853. doi:10.1007/s00264-011-1209-7
- Bacci G, Mercuri M, Longhi A, et al. Grade of chemotherapy-induced
necrosis as a predictor of local and systemic control in 881 patients
with non-metastatic osteosarcoma of the extremities treated with
neoadjuvant chemotherapy in a single institution. Eur J Cancer.
2005;41(14):2079-2085. doi:10.1016/j.ejca.2005.03.036
- Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in
Ewing’s tumor of bone: analysis of 975 patients from the European
Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol.
2000;18(17):3108-3114. doi:10.1200/JCO.2000.18.17.3108
- Balamuth NJ, Womer RB. Ewing’s sarcoma. Lancet Oncol.
2010;11(2):184-192. doi:10.1016/S1470-2045(09)70286-4
- Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in
patients with Ewing’s sarcoma using the surveillance, epidemiology,
and end results (SEER) program database. Cancer Epidemiol.
2015;39(2):189-195. doi:10.1016/j.canep.2014.12.012
- Bajpai J, Panda GS, Chandrasekharan A, et al. Adolescent-adult
nonmetastatic Ewing sarcoma-Experience from a large developing
country. Pediatr Blood Cancer. 2021;68(9):e29081.
doi:10.1002/pbc.29081
- Wunder JS, Paulian G, Huvos AG, et al. The histological response to
chemotherapy as a predictor of the oncological outcome of operative
treatment of Ewing sarcoma. J Bone Joint Surg Am.
1998;80(7):1020-1033. doi:10.2106/00004623-199807000-00011
- Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic
osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin
Oncol. 1992;10(1):5-15. doi:10.1200/JCO.1992.10.1.5
- Schwartz CL, Gorlick R, Teot L, et al. Multiple drug resistance in
osteogenic sarcoma: INT0133 from the Children’s Oncology Group. J Clin
Oncol. 2007;25(15):2057-2062. doi:10.1200/JCO.2006.07.7776
- Bielack S, Kempf-Bielack B, Schwenzer D, et al. Neoadjuvante Therapie
des lokalisierten Osteosarkoms der Extremitäten. Erfahrungen der
Cooperativen Osteosarkomstudiengruppe COSS an 925 Patienten
[Neoadjuvant therapy for localized osteosarcoma of extremities.
Results from the Cooperative osteosarcoma study group COSS of 925
patients]. Klin Padiatr. 1999;211(4):260-270.
doi:10.1055/s-2008-1043798
- Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window
therapy for osteosarcoma: results of the St Jude Children’s Research
Hospital OS-91 trial. J Clin Oncol. 2001;19(1):171-182.
doi:10.1200/JCO.2001.19.1.171
- Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of
alkaline phosphatase measurements in patients with osteogenic sarcoma
receiving chemotherapy. Cancer. 1979;43(6):2178-2181.
doi:10.1002/1097-0142(197906)43:6<2178::aid-cncr2820430603>3.0.co;2-9
- Jin Q, Xie X, Yao H, et al. Clinical Significance of the Radiological
Relationship between the Tumor and the main blood vessels in Enneking
IIB Osteosarcoma of the extremities. J Cancer .
2020;11(11):3235-3245. Published 2020 Mar 5. doi:10.7150/jca.42341
- Rodríguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic
factors in ewing sarcoma family of tumors: review of St. Jude
Children’s Research Hospital studies. Cancer. 2007;110(2):375-384.
doi:10.1002/cncr.22821
- Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival
after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer.
2011;57(4):549-553. doi:10.1002/pbc.23040
- Longhi A, Fabbri N, Donati D, et al. Neoadjuvant chemotherapy for
patients with synchronous multifocal osteosarcoma: results in eleven
cases. J Chemother. 2001;13(3):324-330. doi:10.1179/joc.2001.13.3.324
- Sukumaran RK, Rajeshwari B, Sugath S, Chellappan SG, Thankamony P,
Parukuttyamma K. Methotrexate Free Chemotherapy and Limb Salvage
Surgery for Paediatric Osteosarcoma in India. Indian J Orthop.
2018;52(1):58-64. doi:10.4103/ortho.IJOrtho_195_17
- Dharanikota A, Arjunan R, Dasappa A. Factors Affecting Prognosis and
Survival in Extremity Osteosarcoma. Indian J Surg Oncol.
2021;12(1):199-206. doi:10.1007/s13193-020-01277-2
- Ganguly S, Sasi A, Khan SA, et al. Formulation and validation of a
baseline prognostic score for osteosarcoma treated uniformly with a
non-high dose methotrexate-based protocol from a low middle income
healthcare setting: a single centre analysis of 594 patients. Front
Oncol. 2023;13:1148480. Published 2023 Apr 28.
doi:10.3389/fonc.2023.1148480
- Petrilli AS, Brunetto AL, Cypriano Mdos S, et al. Fifteen Years’
Experience of the Brazilian Osteosarcoma Treatment Group (BOTG): A
Contribution from an Emerging Country. J Adolesc Young Adult Oncol.
2013;2(4):145-152. doi:10.1089/jayao.2013.0012
- Song K, Song J, Chen F, Lin K, Ma X, Jiang J. Prognostic nomograms for
predicting overall and cancer-specific survival of high-grade
osteosarcoma patients. J Bone Oncol. 2018;13:106-113. Published 2018
Oct 4. doi:10.1016/j.jbo.2018.09.012
- Lu S, Wang Y, Liu G, et al. Construction and validation of nomogram to
predict distant metastasis in osteosarcoma: a retrospective study. J
Orthop Surg Res. 2021;16(1):231. Published 2021 Mar 30.
doi:10.1186/s13018-021-02376-8
- Yang QK, Lai QY, Wang Y, Wang Y, Yao ZX, Zhang XJ. Establishment and
validation of prognostic nomograms to predict overall survival and
cancer-specific survival for patients with osteosarcoma. Neoplasma.
2021;68(2):434-446. doi:10.4149/neo_2020_200617N639
- Zhang J, Yang J, Wang HQ, et al. Development and validation of a
nomogram for osteosarcoma-specific survival: A population-based
study. Medicine (Baltimore) . 2019;98(23):e15988.
doi:10.1097/MD.0000000000015988
- Gao F, Zhou Y, Zhao R, Ren Y. Establishing a novel prognostic tool for
Ewing sarcoma patients: Surveillance, Epidemiology, and End Results
database analysis. Medicine (Baltimore). 2020;99(46):e23050.
doi:10.1097/MD.0000000000023050
- Zhang J, Pan Z, Yang J, Yan X, Li Y, Lyu J. A nomogram for determining
the disease-specific survival in Ewing sarcoma: a population study.
BMC Cancer. 2019;19(1):667. Published 2019 Jul 5.
doi:10.1186/s12885-019-5893-9
- Zhou Q, Wu ZY, Lin ZQ. A nomogram to predict prognosis in Ewing
sarcoma of bone. J Bone Oncol. 2019;15:100223. Published 2019 Feb 12.
doi:10.1016/j.jbo.2019.100223
- Bosma SE, Lancia C, Rueten-Budde AJ, et al. Easy-to-use clinical tool
for survival estimation in Ewing sarcoma at diagnosis and after
surgery. Sci Rep. 2019;9(1):11000. Published 2019 Jul 29.
doi:10.1038/s41598-019-46721-8
- Zhou Z, Wang J, Fang L, Ma J, Guo M. A nomogram for predicting overall
survival in patients with Ewing sarcoma: a SEER-based study. BMC
Musculoskelet Disord. 2020;21(1):737. Published 2020 Nov 12.
doi:10.1186/s12891-020-03706-3
- Shi J, Yang J, Ma X, Wang X. Risk factors for metastasis and poor
prognosis of Ewing sarcoma: a population based study. J Orthop Surg
Res. 2020;15(1):88. Published 2020 Mar 4.
doi:10.1186/s13018-020-01607-8
- Nataraj V, Batra A, Rastogi S, et al. Developing a prognostic model
for patients with localized osteosarcoma treated with uniform
chemotherapy protocol without high dose methotrexate: A single-center
experience of 237 patients. J Surg Oncol. 2015;112(6):662-668.
doi:10.1002/jso.24045
- Wagner MJ, Livingston JA, Patel SR, Benjamin RS. Chemotherapy for Bone
Sarcoma in Adults. J Oncol Pract. 2016;12(3):208-216.
doi:10.1200/JOP.2015.009944
- Bajpai J, Chandrasekharan A, Simha V, et al. Outcomes in
Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma
Treated With OGS-12, a Novel Non-High-Dose Methotrexate-Based,
Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center.
J Glob Oncol. 2018;4:1-10. doi:10.1200/JGO.17.00137
- Mailankody S, Kumar VS, Khan SA, Banavali SD, Bajpai J.
Resource-appropriate selection of osteosarcoma treatment protocols in
low- and middle-income countries. Pediatr Blood Cancer.
2022;69(3):e29540. doi:10.1002/pbc.29540
LEGENDS:
Figure 1: Figure 1 is a CONSORT diagram depicting the number of patients
analyzed in the current study
Figure 2A[i]: Figure 2A[i] is a Kaplan-Meier curve depicting
event-free survival for the patients with non-metastatic osteosarcoma:
derivation cohort (n=342)
Figure 2A[ii]: Figure 2A[ii] is a Kaplan-Meier curve depicting
event-free survival for the patients with non-metastatic osteosarcoma:
derivation cohort (n=158)
Figure 2A[iii]: Figure 2A[iii] is a Kaplan-Meier curve depicting
event-free survival for the patients with non-metastatic osteosarcoma:
derivation cohort (n=500)
Figure 2B: Figure 2B is a nomogram depicting the prognostic model for
non-metastatic Ewing’s Sarcoma
Figure 2C: Figure 2C is a nomogram depicting the prognostic model for
metastatic osteosarcoma
Figure 2D: Figure 2D is a nomogram depicting the prognostic model for
metastatic Ewing’s Sarcoma